Colesevelam is safe and effective at lowering LDL cholesterol in children with familial hypercholesterolemia

摘要

During the American Heart Association Scientific Sessions in November 2008, Evan Stein from the Metabolic and Atherosclerosis Research Center in Ohio, OH, USA, presented data on the use of colesevelam, a bile-acid sequestrant, to treat children with heterozygous hypercholesterolemia. The drug acts to lower LDL cholesterol in children with the disease, and was well tolerated by patients.A total of 191 patients aged 10-17 years with familial hypercholesterolemia were assigned to three groups; placebo, 1.875 g/day colesevelam and 3.75g/day colesevelam in a randomized, double-blind study.